- Breaking News Japan welcomes reelection of Karzai as Afghan president, vows support
- Breaking News U.S. editorial excerpts -2-
- Breaking News 3RD LD: Blast in Pakistan's Rawalpindi kills at least 30
- Breaking News Obama reaffirms support for Karzai as run-off is cancelled
AVI Biopharma, Inc. Review in Progress.
0 Comments | M2 Presswire, March, 2008
M2 PRESSWIRE-25 March 2008-Street Tips: AVI Biopharma, Inc. Review in Progress(C)1994-2008 M2 COMMUNICATIONS LTD
RDATE:25032008
Streetinvesting.com has now resumed our progressive review of AVI Biopharma, Inc. (NASDAQ:AVII) as it opened up $0.03 nearing its 52 week low of $1.00 on below average volume midday trading Tuesday, March 25, 2008. Based on the Company's most recent news release; we will be progressively reviewing the impact of the markets and the effects of their developments. We will be providing updates and analyst opinions as new stories unfold.
Make sure to visit www.streetinvesting.com to keep updated and signup for free with no credit card for market reports and analytical plays.
Our research resources have been...
- Made from scratch: When Honda built a plant in Alabama it also built a workforce-using local workers who had no experience in making cars - Recruitment & Hiring
- Portfolio forecasting tools: what you need to know
- Kemarie McMinn Named Executive Vice President of Halo Debt Solutions, Inc.
- Halo Debt Solutions, Inc. Supports Push Toward Industry Regulation
- Traction Named #1 Interactive Agency for 2009 by BtoB Magazine
- Halo Debt Solutions, Inc. Gives Debt Settlement a Face-Lift
- Banking technology, technological learning and competition: comparative case studies in Thai banking
- Empirically assessing the impact of BPR on banking firms